Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

A Global Alliance Established for Sharing Genomic Data

By BiotechDaily International staff writers
Posted on 24 Jun 2013
A shared framework for analyzing and distributing genomic information should soon speed medical progress and innovations.

Nearly 70 organizations in research, healthcare, and disease advocacy have agreed to take part in a global alliance focused on standardizing and sharing genomic and clinical data. “The cost of genome sequencing has fallen one-million fold in the past several years, fueling an explosion of information about the genetic basis of human health and disease,” wrote the authors of a white report announcing the alliance. In principle, this plethora of genome data could reveal the genetic basis of inherited and infectious disease, cancer, and drug responses. “However, we are not organized to seize this extraordinary opportunity.”

The problem is that the data are “collected and studied in silos: by disease, by institution, and by country,” reported the investigators. Tools and techniques for study are not standardized and can be incompatible. Furthermore, there are not agreed upon regulatory procedures that respect the privacy of people who have donated their genome sequences to research projects. All this “inhibits learning and improving healthcare,” they reported.

To address these problems, the alliance will develop international standards and infrastructure to share and integrate data in a controlled, secure, and interpretable way that upholds patient autonomy and right to privacy. Participants in the accord include the US National Institutes of Health (Bethesda, MD, USA), the Wellcome Trust Sanger Institute (Hinxton, Cambridgeshire, UK), and the Beijing Genomics institute (BGI; Beijing, China), as well as universities and hospitals.

The large pool of genomic sequences and medical data expected from the alliance is the sort of dataset required to determine the genetic basis of both cancer and rare diseases, recently reported an item in the New York Times. The mutations underlying these disorders are just too rare to be studied in data collected at a single institution.

A disease might occur in one in 1,000 or one in 100,000 babies, according to Dr. David Altshuler, deputy director and chief academic officer at the Broad Institute of Harvard University (Cambridge, MA, USA) and the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA). A medical center might never see a child with that disease, or might see just one. “Since everyone sees zero or one, no one ever learns,” Dr. Altshuler said.

In spite of the commendable goals of the alliance, researchers may be reluctant to share hard-won genomic information, a “valuable commodity,” the researcher noted. A big question for the group is whether it can convince institutions to share their most meaningful data. “The mission is unquestionably worthy,” said cardiologist Dr. Eric Topol, director of the Scripps Translational Science Institute (La Jolla, CA, USA), which has not yet considered joining the alliance. But, he adds, “it means taking the walls down, and that’s tricky—because you’ve got each center wanting to hold on to its own data, and the loss of control is a very difficult concept.”

Related Links:
US National Institutes of Health
Wellcome Trust Sanger Institute
Massachusetts Institute of Technology



WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Mosquitoes are known to infect people and animals with West Nile virus. Studying West Nile virus infection in mice, researchers have shown that the antiviral compound interferon-lambda tightens the blood-brain barrier, making it harder for the virus to invade the brain (Photo courtesy of the CDC – [US] Centers for Disease Control and Prevention).

Interferon-Lambda Prevents West Nile Virus from Crossing the Blood-brain Barrier

The cytokine interferon-lambda prevents West Nile virus from infecting brain cells by reducing transport of large molecules across the blood-brain barrier. Although interferon-lambda [also known as... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

27 May 2015 - 28 May 2015
02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.